MolMed announces the enrolment of the first patient in the United States, initiating the cross-Atlantic expansion of the pivotal Phase III trial of its proprietary TK cell/gene therapy for high-risk leukaemia patients.
http://ireport.cnn.com/docs/DOC-1051789?ref=feeds%2Flatest
http://ireport.cnn.com/docs/DOC-1051789?ref=feeds%2Flatest
No comments:
Post a Comment